Abstract
The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn’s disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 833-842 |
| Number of pages | 10 |
| Journal | Digestive diseases and sciences |
| Volume | 62 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- Adalimumab
- Inflammatory bowel disease
- Infliximab
- Therapeutic antibodies
- Therapeutic drug monitoring
- Tumor necrosis factor alpha
ASJC Scopus subject areas
- Physiology
- Gastroenterology
Cite this
The Impact of Therapeutic Antibodies on the Management of Digestive Diseases : History, Current Practice, and Future Directions. / Sofia, Mark (Anthony); Rubin, David T.
In: Digestive diseases and sciences, Vol. 62, No. 4, 01.04.2017, p. 833-842.Research output: Contribution to journal › Editorial
}
TY - JOUR
T1 - The Impact of Therapeutic Antibodies on the Management of Digestive Diseases
T2 - History, Current Practice, and Future Directions
AU - Sofia, Mark (Anthony)
AU - Rubin, David T.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn’s disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.
AB - The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn’s disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.
KW - Adalimumab
KW - Inflammatory bowel disease
KW - Infliximab
KW - Therapeutic antibodies
KW - Therapeutic drug monitoring
KW - Tumor necrosis factor alpha
UR - http://www.scopus.com/inward/record.url?scp=85012874237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012874237&partnerID=8YFLogxK
U2 - 10.1007/s10620-017-4479-0
DO - 10.1007/s10620-017-4479-0
M3 - Editorial
VL - 62
SP - 833
EP - 842
JO - American Journal of Digestive Diseases and Nutrition
JF - American Journal of Digestive Diseases and Nutrition
SN - 0163-2116
IS - 4
ER -